POEMS syndrome is a rare blood disorder in which abnormal plasma cells (a type of white blood cell) produce a protein that damages nerves, organs, and skin throughout the body. The name is an acronym for its hallmark features: polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes. It affects roughly 3 people per million, and while it can be serious, survival rates have improved dramatically in recent years.
What the Acronym Means
Each letter in POEMS refers to a category of symptoms the syndrome can cause:
- Polyneuropathy: nerve damage affecting both sides of the body, causing numbness, tingling, and weakness that typically starts in the feet and legs
- Organomegaly: enlargement of organs, most commonly the liver, spleen, or lymph nodes
- Endocrinopathy: hormonal imbalances affecting multiple glands
- M-protein: an abnormal protein produced by cancerous or pre-cancerous plasma cells, detectable in blood tests
- Skin changes: darkening of the skin, excess hair growth, small blood vessel growths, and other visible changes
Not every patient develops all five features. The syndrome is driven by a small population of abnormal plasma cells, almost always producing a specific type of antibody fragment called lambda light chains.
What Causes the Symptoms
The abnormal plasma cells in POEMS don’t just produce a rogue protein. They also trigger the overproduction of a signaling molecule called VEGF (vascular endothelial growth factor), which normally helps the body build new blood vessels. In POEMS, VEGF levels skyrocket, often exceeding 1,040 pg/mL, a threshold that identifies the syndrome with near-perfect accuracy.
Excess VEGF makes blood vessels leaky and causes them to proliferate in places they shouldn’t. This explains many of the syndrome’s seemingly unrelated symptoms: fluid accumulation around the lungs, swelling in the legs, and the small red skin growths (angiomas) that appear in roughly a quarter to nearly half of patients. The nerve damage, organ enlargement, and hormonal disruptions are all thought to stem at least partly from this same cascade of overactive blood vessel signaling.
Nerve Damage Is the Defining Feature
The polyneuropathy in POEMS is not optional. It’s one of two mandatory criteria for diagnosis. It typically begins as numbness or pins-and-needles sensations in both feet, then gradually climbs upward and eventually affects the hands. Over time, motor function declines, and patients may struggle to walk, grip objects, or maintain balance.
This nerve damage often gets misdiagnosed as chronic inflammatory demyelinating polyneuropathy (CIDP), a more common condition that looks similar on initial testing. The distinction matters because CIDP is treated with immune-suppressing therapies that don’t address POEMS. Key differences show up under the microscope: POEMS causes more widespread nerve fiber loss and increased small blood vessel formation around the nerves, while CIDP produces more localized inflammation and distinctive layered scarring around nerve fibers. If you’ve been diagnosed with CIDP but aren’t responding to treatment, POEMS should be considered.
Hormonal Disruption
Endocrine problems appear in up to 68% of patients at diagnosis, and that number climbs to 92% as the disease progresses. The most common hormonal abnormality is hypogonadism, a drop in sex hormones that can cause fatigue, low libido, and menstrual irregularities. Beyond that, patients may develop elevated prolactin levels, underactive thyroid function, abnormal glucose metabolism, adrenal insufficiency, or elevated growth factor levels.
Diabetes and thyroid problems are actually excluded from the formal diagnostic criteria because they’re so common in the general population that they don’t help distinguish POEMS from other conditions. The hormonal disruptions that do count toward diagnosis are less common ones like hypogonadism and adrenal insufficiency.
Skin Changes and Other Signs
Skin abnormalities show up in about 65% to 68% of patients and can sometimes be the earliest visible clue. The most frequent changes are diffuse darkening of the skin (hyperpigmentation), a flushed or ruddy complexion, and bluish discoloration of the fingers and toes. Excess body hair growth, thickened skin, white fingernails, and small cherry-red or capillary skin growths also occur. A rare but distinctive finding called a glomeruloid hemangioma, a specific type of blood vessel growth, appears in only about 3% of cases but is highly specific to POEMS and can precede other symptoms by months or years.
Other features that fall outside the acronym include fluid buildup (pleural effusions, leg swelling, or ascites), an elevated platelet count, and papilledema, which is swelling of the optic nerve visible during an eye exam.
How POEMS Is Diagnosed
Diagnosis requires meeting a specific set of criteria. Three of five major criteria must be present, and two of those three must be polyneuropathy and evidence of a clonal plasma cell disorder (the abnormal cells producing M-protein). The remaining major criteria are bone lesions that appear dense or hardened on imaging, elevated VEGF levels, and the presence of Castleman disease (a related lymph node condition).
At least one minor criterion must also be met, drawn from a list that includes organ enlargement, hormonal abnormalities, skin changes, papilledema, fluid overload, and high platelet counts. Blood and urine tests identify the M-protein. Imaging studies, usually CT scans or PET scans, look for bone lesions. A bone marrow biopsy confirms the plasma cell disorder.
The diagnostic process can take time because POEMS is rare and its symptoms overlap with many other conditions. The median time from first symptoms to diagnosis often stretches to over a year.
Treatment Depends on How Widespread It Is
Treatment strategy hinges on whether the disease is localized or widespread. When imaging reveals only a single bone lesion or a small cluster of lesions in one area, radiation therapy directed at those spots produces reliable clinical responses and can resolve symptoms, including nerve damage, on its own.
When the disease involves multiple bone lesions spread across the skeleton, or when bone marrow is significantly infiltrated, systemic treatment is needed. For patients healthy enough to tolerate it, stem cell transplant offers the best long-term outcomes. A study of transplant recipients found a 4-year progression-free survival rate of nearly 80% and a 4-year overall survival rate of about 93%. At five years, transplanted POEMS patients fared significantly better than multiple myeloma patients undergoing the same procedure, with 91% survival compared to 71%.
For patients who aren’t candidates for transplant, medication-based treatments that target the abnormal plasma cells are used. These have also improved considerably. Among patients treated without transplant, the five-year survival rate rose from about 63% in earlier decades to nearly 88% in the most recent treatment era.
Outlook and Recovery
POEMS syndrome was once considered to carry a grim prognosis, but outcomes have transformed over the past two decades. The median overall survival from diagnosis now exceeds 15 years, and for patients diagnosed in recent years with access to modern treatments, median survival has not yet been reached in studies, meaning most patients are still alive at the end of follow-up periods. Five-year survival rates have climbed from 70% in earlier cohorts to over 92% in the most recent.
Nerve recovery after successful treatment is possible but slow. It can take months to years for sensation and strength to return, and some patients retain residual numbness or weakness. Hormonal problems may persist even after the underlying plasma cell disorder is controlled, requiring ongoing hormone replacement. Regular monitoring for new endocrine problems is important because they can develop at any point during the disease course.